drugset / Trial / NCT01464697

Progesterone for Perimenopausal Night Sweats

NCT01464697

Phase 3 Completed 249 enrolled University of British Columbia
RandomizedSingle-groupQuadruple-blindTreatment

Summary

The purpose of this study is to test whether a oral micronized progesterone reduces the Vasomotor Symptom Score comprised of the number and severity of hot flushes and night sweats in perimenopausal women. Oral micronized progesterone is molecularly identical to human progesterone, a steroid hormone. It is sold by prescription for use to prevent endometrial cancer in women taking estrogen in menopause. This research study will test whether progesterone reduces perimenopausal hot flushes and night sweats. It will also test whether progesterone improves sleep disturbances and anxiety.

Timeline

Start
2011-10
Primary completion
2018-06-01
Completion
2018-06-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Progesterone Other / unclassified 300 mg Oral

Indications

No indication recorded.